XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Product Revenue, Net
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Product Revenue, Net PRODUCT REVENUE, NET
We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $15.6 million during the twelve months ended December 31, 2022.
Sales to AmerisourceBergen Drug Corporation, Cardinal Health, and McKesson Corporation made up 26.8%, 23.1%, and 21.6%, respectively, of our gross product revenue during the twelve months ended December 31, 2022.
The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
Discounts and ChargebacksRebates, Wholesaler and GPO FeesCopay and ReturnsTotal
Balance as of December 31, 2021$— $— $— $— 
Activity related to 2022 sales825 2,721 2,502 6,048 
Credits/deductions issued(683)(1,277)(1,244)(3,204)
Balance as of December 31, 2022$142 $1,444 $1,258 $2,844 
There were no product sales or gross-to-net accruals during the twelve months ended December 31, 2021 or 2020.